2000s

Documents dated 2000–2009.

Page 23 of 25 — 2,476 documents
Title / Summary Year AR226 Docket Hash ID Pages
This document details an acute toxicity test of a mixture containing 3% perfluorooctanesulfonate (PFOS) on the aquatic invertebrate Corophium volutator, conducted using ASTM E1367-90 methodology, with results potentially influenced by impurities in the test sample. 2000 AR226-0697 QJ0ZrBdexVdJyqx6Vrvb2wGb5 34
The document contains an exploratory 28-day oral toxicity study on PFOS and other chemicals, submitted by 3M under a claim of confidentiality, detailing the effects of these substances in rats. 2000 AR226-0153 25VQMEqYyBx1JVBZGpnRmw95 1
The document contains various pharmacokinetic studies related to perfluorooctane sulfonate (PFOS) conducted by 3M, including skin absorption studies in rabbits and analytical data on serum measurements from in-life studies in rats. 2000 AR226-0154 e5vp9bMD02YxmvMoV3Y5Vw6aq 6
This document details an acute toxicity test of a mixture containing perfluorooctanesulfonate (PFOS) on the aquatic invertebrate Corophium volutator, using a method based on ASTM E1367-90, with results potentially affected by the presence of impurities in the test sample. 2000 AR226-0730 5RgQ93ogZVZJ1w5p387G9JwD 34
This document from 3M provides serum measurements for perfluorooctanesulfonate (PFOS) from two pharmacokinetic studies conducted on rats, detailing the analytical results and offering assistance to the EPA in understanding the toxicological information. 2000 AR226-0160 VKyEyZb3GOXbzvDg4oDJZ57V8 22
This final report details a pharmacokinetic study conducted by 3M on the perfluorinated compound FC-99 (T-6053) in rabbits, finding that fluorine was detected in liver tissue after a single intravenous dose of 20 µg/kg, indicating that the perfluorooctanesulfonate salt form does not affect the availability of total organic fluorine in the 2000 AR226-0157 QM4NegreReRMbgOLkarj3XmJ6 88
The document is a final report from 3M Environmental Laboratory detailing a single-dose dermal absorption/toxicity study of the perfluorinated compound FC-99 (T-6053) in rabbits, which found no significant differences in liver fluorine levels between treated and control groups, indicating low dermal absorption of the substance. 2000 AR226-0158 gaxkQK2jg9wbwgjJX0pJawYDe 135
The document outlines research proposals and studies by Kendall B. Wallace at the University of Minnesota Duluth focused on understanding the biochemical and molecular mechanisms of perfluoroalkyl compounds, particularly perfluorooctane sulfonate (PFOS), with the goal of establishing reliable biomarkers for exposure and biological effects related to health risks. 2000 AR226-0165 VG6O186xezYB5KO2gaE7RYzDg 12
This report details the effects of a single acute dose of PFOS (40 mg/kg) and N-EtFOSE (160 mg/kg) on catalase and acylCoA oxidase gene expression and enzyme activity in liver tissue from rats and guinea pigs, as part of a study conducted by 3M. 2000 AR226-0171 G5Oem37jNoadbqrYoNXjokken 6
The document discusses various studies and analyses related to perfluoroctane sulfonate (PFOS) in human sera, focusing on blood fluoride levels and the implications of organic fluorine concentrations in relation to exposure and industrial hygiene controls. 2000 AR226-0174 KVk7zN1maQazbB2kmvmNbz20 7
The document is a final report of a pilot teratology study in rats (Project No. 154-158) conducted by Hazleton Laboratories for 3M, focusing on the effects of perfluoroctane sulfonate (PFOS). 2000 AR226-0173 gbmx49pXL3aJYMN4bM164RMNa 48
The document outlines ongoing studies related to Perfluorooctane Sulfonic Acid Potassium Salt (PFOS) being conducted by Covance Laboratories and 3M, including a 104-week dietary chronic study in rats and various toxicity and pharmacokinetic studies, with interim data provided for these investigations. 2000 AR226-0179 8VmG6jaBy2oz8ymMp9KYe2Emk 12
This document outlines a research project by 3M, led by Deanna J. Luebker, investigating the mechanism by which perfluorooctane sulfonic acid (PFOS) induces adverse effects on peri-/postnatal development in rats, specifically focusing on its inhibition of HMG-CoA reductase and potential toxicity mitigation through co-administration of mevalonate. 2000 AR226-0183 KDx86Xbva76OwjkYp628eN8X 16
The document outlines ongoing environmental studies on perfluorooctanesulfonates (PFOS) being conducted by various laboratories, including 3M Environmental Laboratory and Wildlife International, with expected completion dates in 2000 for studies on physical/chemical properties, environmental fate, transport, and ecotoxicity tests. 2000 AR226-0184 Gm1vo5z4NaQvb5Orn3GaNKQpV 12
The document details an acute toxicity test of a PFOS-containing mixture (FC-602) on the aquatic invertebrate Corophium volutator, conducted using standard methods to assess the toxicity of the fluorochemical component. 2000 AR226-0847 10yj86zXxg01Nj4M8pd6bx04j 35
The document details an acute toxicity test of a mixture containing 1.30% perfluorooctanesulfonate (PFOS) on the aquatic invertebrate Corophium volutator, conducted using ASTM E1367-90 methodology, with results potentially influenced by impurities in the test sample. 2000 AR226-0861 rBMgZKz7zOyQ8Q9dRL7OE4rxr 34
The document contains attachments to a letter discussing various studies and information on acute toxicity and genotoxicity related to perfluorooctane sulfonate (PFOS) and its derivatives, including tests conducted by Biosearch, Inc. and Hazelton Washington. 2000 AR226-0291 zoGqppdxaobJJRVmMLzep8L0B 4
The document includes various studies and tests conducted by Riker Laboratories and other institutions on the acute toxicity, immunotoxicity, genotoxicity, and repeated-dose toxicity of N-ethylperfluorooctane sulfonamidoethyl acrylate (T-3493), a perfluorinated compound associated with 3M. 2000 AR226-0304 rp7JnEa7G8x3NKqQg9grEwx4G 10
The document details acute toxicity studies conducted by Riker Laboratories on N-ethyl perfluorooctane sulfonamido ethyl methacrylate (T-3494), including oral toxicity, skin irritation, and ocular irritation tests in albino rats and rabbits, as part of a safety evaluation for 3M. 2000 AR226-0312 jy3Ry3eOXoEggKg92pBNb8EN5 10
This document contains studies and evaluations regarding the mutagenic activity of N-methylperfluorooctane sulfonamidoethyl acrylate (T-5869) conducted by NOTOX, including results from the Ames Salmonella test and chromosome aberration tests, all compliant with GLP standards. 2000 AR226-0317 6BBoN297mVo3o8Q2p3Y1Rm7K6 24
The document contains attachments related to studies on the acute toxicity and pharmacokinetics of perfluorooctane sulfonate (PFOS) and its derivatives, specifically detailing various toxicity tests conducted by 3M and other laboratories. 2000 AR226-0320 JJ2p3D5EvGxRzvmaREkM00nYv 32
3M submitted a revised "Use and Exposure Information Profile" for perfluorooctane sulfonic acid (PFOS) to the EPA, providing additional details on their environmental and industrial hygiene management of the substance at their manufacturing facilities. 2000 AR226-0927 YGRVkw92Ybz8xBn6q7JYYeG0N 1
The document is a letter from the EPA to 3M Company, informing them about the enclosed TSCA Administrative Record on PFOS and related compounds, which includes submissions from 3M and DuPont, and outlines future submission protocols. 2000 AR226-0929 damXmEO1Q2NOxg82D16r71kDq 1
The document is a letter from 3M to the EPA detailing the CAS numbers and names of perfluorooctanyl chemistry products that 3M plans to phase out, as part of their commitment to discontinue manufacturing these substances. 2000 AR226-0931 GKwBLnjMrx5EOnKmvyG505xZV 5
Dainippon Ink & Chemicals, Inc. is confirming a meeting with the U.S. EPA on September 15th regarding PFOA/PFOS, with representatives attending due to the absence of the President of the Additives & Chemicals Division. 2000 AR226-0933 DDzd1Gkba61e898jkB6z33MRo 1
This document is a letter from 3M to the EPA formalizing a response regarding the non-confidential status of chemical names and phase-out dates for perfluorinated compounds, specifically stating that the complete phase-out dates for Industrial Surfactants and Fire Fighting Foams are not considered confidential business information. 2000 AR226-0932 dn45wQEGGgOR0BKD1Dr1o0Qxq 3
Dainippon Ink & Chemicals Inc. is requesting a meeting with the U.S. EPA on September 15, 2000, to discuss the issue of PFOS, acknowledging the EPA's support for 3M's decisions regarding the substance. 2000 AR226-0934 dn9NrMgZnzbNnYK3Yd5Ndd6GR 2
The document provides a voluntary use and exposure information profile for perfluorooctane sulfonate (PFOS) and its various salt forms produced by 3M Company, detailing their chemical identification, manufacturing processes, and distribution estimates. 2000 AR226-0928 5L8w5gqZewZZREVznK3DK1YNN 34
The document is a communication from Deltoppon Ink & Chemicals Inc. to the U.S. EPA regarding a meeting scheduled for September 15, 2000, to discuss various issues including PFOA and other perfluorinated compounds. 2000 AR226-0935 V3NgpN025RJ7QKMdLGRMx6kLZ 1
The document is a letter from the EPA's Office of Prevention, Pesticides and Toxic Substances to Masanobu Yumoto of Dainippon Ink & Chemicals, discussing a meeting to address technical uses of PFOS and clarifying that the meeting will not involve negotiations. 2000 AR226-0936 Yj4a78e5RNzp0GVB9n1NjrXEK 1
This document discusses Kidde Fire Fighting's foam concentrate products, clarifying that they do not contain PFOS due to their use of specialty fluorochemicals from the TFE process, and addresses concerns regarding the EPA's consideration of extending the phase-out plan for 3M's foam concentrates. 2000 AR226-0940 XOqJKOLB95G0KqXr2bQ2o6dKd 1
IKEA's Quality Department inquired about the environmental and health effects of DuPont's Teflon-based finish in comparison to PFOS, as they are phasing out products treated with 3M's Scotchgard due to EPA's concerns over perfluorinated compounds. 2000 AR226-0941 NNm9Eqg5zE7GmMpXKexBdzRGD 1
The Boeing Company is informing the EPA that it has been using FC-98, a fluorinated compound essential for hydraulic fluid in aircraft, and is concerned about its impending phase-out by 3M, the sole manufacturer, as there are no alternatives available. 2000 AR226-0943 NE9KEXnqp547LOQxvMYy9k1QE 5
The document is a note summarizing a meeting held on September 15, 2000, to discuss alternatives to PFOS for carpet treatment, attended by representatives from Shaw Industries and the EPA. 2000 AR226-0945 KJwV4B6Qp8kMJ20G5qkQOLR8w 1
The document is a revised PFOS hazard assessment from October 23, 2000, by Karen Lannon, which includes minor textual corrections from the original version but states that the conclusions remain unaffected. 2000 AR226-0946 qdE0p01R4X5Zvy1bBeMJgBRLK 29
3M is providing additional voluntary information to the EPA regarding perfluorooctane sulfonates and related compounds, including various CAS numbers and chemical forms, as part of ongoing discussions about fluorochemistry. 2000 AR226-0333 qddeLBwY5qg4xO8Q8j6bbx8E5 20
The document is a status report on the Telomer Research Program presented to the U.S. EPA on October 23, 2000, detailing the program's organization, guiding principles, and management structure focused on data gathering related to telomer manufacturers, including companies like DuPont and Daikin. 2000 AR226-0947 g2zxGw04wGD0VJ2ee6VDX54mL 153
The document details an acute inhalation toxicity study of T-2306 CoC, a perfluorinated compound from 3M, conducted on rats to determine its median lethal concentration (LC50). 2000 AR226-0954 5yYQ6ZELQJ54Q8JBzXbeBZ10 42
This document reports on a pharmacokinetic study of T-6246 (FC-95) in rabbits, revealing that the half-life of perfluorooctanesulfonate anion in serum and liver is one month or greater, with detectable fluorine levels in serum after doses of 0.12 mg/kg and 0.60 mg/kg but not after 0.012 mg 2000 AR226-0948 6ba7QEdxZoDdqNvxevqnkdQEo 281
Following negotiations, 3M announced it will voluntarily phase out perfluorooctanyl sulfonate (PFOS) chemistry used in various products, with the EPA indicating it will monitor the situation and take further regulatory actions if necessary. 2000 AR226-0000 dYJo0wb5k093M2QdONz7NkbDR 1
This document is a correspondence from Larry R. Zobel of 3M to Dr. Oscar Hernandez at the US EPA, providing additional documents related to studies on PFOS and PFOA that were inadvertently omitted from a previous package. 2000 AR226-0001 k6vp1Jyo3oBMEE4xrLaYaBrjE 1
The document contains studies and information regarding the acute toxicity of perfluorooctane sulfonate-related compounds, specifically focusing on T-3421 (PFOS) and FOSA, conducted by Riker Laboratories for 3M between 1983 and 1999. 2000 AR226-0963 rx4eRgdo52QrOynrdmwD47rzE 13
The document contains attachments to a letter to C. Auer dated May 18, 2000, discussing studies and information related to perfluorooctane sulfonate (PFOS) and N-ethyl perfluorooctanesulfonamide (N-EtFOSA) that are in 3M's possession, believed to be part of the FIFRA docket. 2000 AR226-0377 gaoGgoELOLz7dKqErGDDevpXJ 2
3M submitted additional information to the EPA regarding perfluorooctane sulfonates and related compounds, including details on N-ethylperfluorooctane sulfonamidoethanol, N-methylperfluorooctanesulfonamidoethyl acrylate, and other perfluorinated compounds. 2000 AR226-0378 aJ578JLXe6oKb0jrxk9aKNQ2B 8
The document contains attachments to a letter regarding toxicology studies on PFOA, detailing various acute toxicity studies conducted on rats and rabbits by different laboratories, including inhalation and oral toxicity assessments. 2000 AR226-0417 xjb1yeR0RRNY70ooZ2985qnvy 7
3M is providing the EPA with supplemental information on perfluorooctanoic acid (PFOA) and perfluorooctane sulfonates (PFOS) that includes studies on their environmental and health effects as part of ongoing discussions regarding fluorochemistry. 2000 AR226-0416 jmON1rv6mnJOzDGMeQGXM1m0Q 28
The document contains attachments related to toxicology studies and mutagenicity evaluations of PFOA and its derivatives conducted by various laboratories, including reports on cell transformation, cytotoxicity, and chromosomal aberrations. 2000 AR226-0428 k6YOvr6bpoK5kga0e2XbbmqnE 19
The document reports on the analysis of FC-143 content in serum and liver samples from a 90-day subacute toxicity study in rhesus monkeys, indicating adverse effects at higher dosage levels compared to a previous rat study, with notable differences in accumulation between species. 2000 AR226-0448 xqQr8ymOgq6XedDOEKMjDdzm 2
The document reports on a study conducted by Southern Research Institute to determine the percent protein binding of perfluorohexane sulfonate, perfluorooctane sulfonate, and perfluorooctanoate in human, rat, and monkey plasma, as well as various human-derived plasma protein fractions. 2000 AR226-1354 J32RwgxJdRv3Qr3OMor8560OO 47
3M submitted a TSCA 8(e) notice to the EPA regarding a 2-year rat feeding study on N-Ethyl perfluorooctylsulfonamido ethanol (N-EtFOSE), indicating a statistically significant increase in benign liver tumors in high dose female rats, corroborating earlier findings from 1988. 2000 AR226-0974 dnBojOo7J8XLJyo3DGV8V7V4e 2
The document is a correspondence from Mary Dominiak of the EPA discussing the proposed Significant New Use Rule on PFOS, a chemical of concern in AFFF, and providing information on how to submit comments on the rule. 2000 AR226-0975 v6xeD2XoyBRm04rv5LKpbYMyb 8
3M submitted a draft Initial Assessment Report on Perfluorooctane Sulfonic Acid (PFOS) to the EPA, detailing available data and evaluations as part of their ongoing dialogue regarding fluorochemistry. 2000 AR226-0976 NeBZ0rkr91BqLodZ9gnvK8jeQ 2
This document is a cover letter from 3M to the EPA, enclosing a draft initial assessment report on perfluorooctane sulfonic acid (PFOS) that evaluates its exposure and biological effects, indicating that current data suggests no adverse health effects associated with human serum levels or environmental concentrations of PFOS. 2000 AR226-0977 5X09egN1NVRb2BpqeROgKzLN 2
This is a letterhead cover page from 3M Specialty Materials, dated December 22, 2000, with no analytical content retained in the OCR. 2000 AR226-0979 LJZ34NojkJwLNOx3D47gaYjO3 7
The document is a final report from Covance Laboratories detailing a study on the L5178Y TK +/- Mouse Lymphoma Forward Mutation Assay conducted with N-EtFOSE (3M Study No.: T-6316.12), submitted to 3M Corporate Toxicology, and confirms compliance with Good Laboratory Practice regulations. 2000 AR226-0983 KJddBpGaQEM8N1k41jBZ7RVKQ 30
The document is a report amendment regarding Protocol 418-009 for a combined oral fertility, developmental, and perinatal/postnatal reproduction toxicity study of N-EtFOSE in rats, issued by Primedica Corporation, which includes a correction to the dosage administration notation without affecting the study results. 2000 AR226-0986 6xwOELk5pLQeDDxg97dZnZbE 3
The document is a final report on a toxicokinetic study of Perfluorooctane Sulfonamide (PFOSA) conducted by 3M, which found that PFOSA is metabolized to PFOS in rats, with PFOSA showing a liver half-life of 5.2 days and serum half-life of less than 4 days. 2000 AR226-0993 o9vYvkz775MKYR4XMOdwdoRER 18
The document contains summaries of various toxicology and pharmacokinetic studies related to perfluorooctanoic acid (PFOA) and its derivatives, specifically focusing on studies conducted by 3M and Riker Laboratories involving rabbits and rats. 2000 AR226-0453 qknMVv1KEVp0zDjm5bervQLBn 121
The document is a final report from 3M Environmental Laboratory detailing a single-dose dermal absorption/toxicity study of a t-butyl ammonium salt of perfluorooctanoate (PFOA) in rabbits, which found that liver and serum levels of total organic fluorine were below practical quantitation limits, indicating minimal absorption. 2000 AR226-0454 yk7k3Mn00E8wv0rakM6m0d44E 233
The document details toxicology studies on PFOA (referred to as T-2998CoC) conducted by Riker Laboratories, Inc. for 3M, including an oral rangefinder study in pregnant rats to establish dosing levels for subsequent teratology studies. 2000 AR226-0462 7OJyYYdaQD2Qgz43pgv7EVwOE 9
The document contains attachments related to toxicology studies and epidemiological investigations on PFOA, focusing on health status and mortality among workers exposed to perfluorooctanoic acid at various production plants, including summaries of multiple studies conducted by different researchers. 2000 AR226-0469 ZJoDBDewBKXmJdqdr8rR1VdqY 9
The document discusses toxicology studies on PFOS and N-EtFOSE, highlighting severe maternal toxicity and reduced fetal body weights observed in a study conducted by Covance, as reported in correspondence from E. Marshall Johnson to William C. McCormick, III. 2000 AR226-0529 gaXzZEE5Gk6wMoDBGa8J0LRMJ 3
This document includes attachments to a letter dated May 25, 2000, discussing toxicology studies and other information on PFOA, along with a letter from E. Marshall Johnson to William C. McCormick, III, regarding teratology studies on PFOS and ethyl FOSE, dated November 12, 1982, which concludes that the test substances pose no unique hazard to development. 2000 AR226-0531 ga7LXODdb4rmy7aXrRErmR8pG 3
3M submitted a supplemental TSCA Section 8(e) notice to the EPA regarding N-Ethyl Perfluorooctyl Sulfonamido Ethanol (N-EtFOSE) and Perfluorooctane Sulfonate (PFOS), including an amended final report on a two-generation rat reproduction study that found no significant effects on pup survival or growth at a specific dosage 2000 AR226-0555 RaQYM72RLgeBY0ZKXmZawebQX 4
The document is a final report amendment regarding a combined oral fertility, developmental, and perinatal/postnatal reproduction toxicity study of N-EtFOSE in rats, indicating a correction to the dosage administration notation without affecting the study results. 2000 AR226-1363 R93VqLz4MDnbJwnxZLxyyLVB 3
The document discusses laboratory-scale thermal degradation studies of perfluorooctanesulfonate (PFOS) and related substances, including FC-807A and FC-1395, to evaluate their potential environmental impact and sources of PFOS. 2000 AR226-1366 375zwg6qyOV91ovEBd2mBqq7y 13
This document is a draft initial assessment report prepared by 3M on perfluorooctane sulfonic acid (PFOS) and its salts, detailing identity, exposure, and environmental considerations related to the substance. 2000 AR226-0978 gaYG5Ve7L605zoG7NMQozLq6V 381
This is a cover page from Pace Analytical Services, Inc. for the 3M Multi-city Food Study, prepared under contract for 3M with project number 1039292. 2000 AR226-1698 kDJwDaa06DdDm0vkMwRLwX90B 1
This report summarizes the effectiveness of a 3M wastewater treatment system using Granular Activated Carbon (GAC) to reduce PFOA concentrations to below detection limits, demonstrating consistent low effluent concentrations and an estimated adsorption capacity of approximately 6.0 mg PFOA per gram of activated carbon. 2000 AR226-1699 DGw2QVpe9RR6r2023X5LR8GXa 6
The document reports on a study conducted by Dr. U. Noack-Laboratorium on the toxicity of 1-Decanol, 3,3,4,4,5,5,6,6,7,7,8,8,9,9,10,10,10-heptadecafluoro to terrestrial plants, specifically focusing on seedling emergence, in compliance with 2000 AR226-1433 nL2b2vbgerBdyLN3MwXzRNe2 51
The document is a final report on a cross-fostering study of PFOS (perfluorooctane sulfonate) in rats, detailing the study's methods, results, and conclusions as part of a regulatory compliance effort. 2000 AR226-0553 44xQb5qmm4zGxMp7Xz6mBvM1N 257
The document is a final report from Boston University detailing a study funded by 3M, which found that perfluorooctanesulfonate (PFOS) activates both PPARa and PPARy receptors, indicating its potential role in altering lipid metabolism and other physiological processes. 2000 AR226-1723 RJ7jGOVkrVw892QGLxe2VwvGk 55
The T-6295.28 Final Report details a study sponsored by 3M to analyze liver enzymes, glycogen levels, and PFOS concentration in liver samples from rats treated with varying doses of Perfluorooctane Sulfonate (PFOS) during a one-generation reproduction study. 2000 AR226-1725 5byMXopxe7ZwXZNZraMGJRVnN 13
The document is a toxicological summary of a dietary acute study on perfluorooctanesulfonate (PFOS) conducted on mallards, detailing the test substance's purity, methods, and experimental design, including exposure and recovery periods. 2000 AR226-1734 7eJQeLrZeryo1wJGjNkpB1bj 11
The document summarizes a dietary chronic pilot reproductive study on the effects of perfluorooctanesulfonate (PFOS) on adult mallards, detailing the experimental design, exposure levels, and evaluation of health and reproductive outcomes over a 20-week period. 2000 AR226-1737 pp8gvqRb7r1zw7rV82gJYpZYB 12
The document is a final report of a pilot reproduction study on PFOS conducted with mallards, submitted to 3M Corporation by Wildlife International, Ltd., and completed on December 18, 2003, in compliance with Good Laboratory Practice standards. 2000 AR226-1738 2Nrd5qKXLjGGXm47r4YQkXrJN 125
The document is a final report of a pilot reproduction study on PFOS conducted with mallards by Wildlife International, Ltd. for 3M Corporation, completed on December 18, 2003, and compliant with Good Laboratory Practice Standards. 2000 AR226-1742 ba61x2Kevq1Q6emYjqKDRJBQg 125
The document is a final report detailing a pharmacokinetic study of potassium perfluorooctanoate (PFOA) in cynomolgus monkeys, conducted by Southern Research Institute for 3M Corporation, which found that the terminal half-life of PFOA in serum varied between male and female monkeys, with concentrations declining over time but remaining detectable for an extended period. 2000 AR226-1781 DGzzVxE5EnaE1DEjQJDr5MaZa 60
The document is a Toxicological Summary of a dietary acute study on Perfluorooctanesulfonate (PFOS) conducted on Northern Bobwhite quail, detailing changes in the purity of the test substance and the methodology used in the study. 2000 AR226-1746 gDY0vMR674gv6X5jw7kq1RMbq 11
This document is a toxicological summary of a dietary acute study on perfluorooctanesulfonate (PFOS) conducted on Northern Bobwhite quail, detailing the test substance's purity, methods used, and the study's timeline and design. 2000 AR226-1749 LXMk8oL0Rv1L8R8Eg27OmZoQ 11
This document is the final report of a pilot reproduction study on PFOS conducted by Wildlife International, Ltd. for 3M Corporation, which was completed on December 18, 2003, and adhered to Good Laboratory Practice Standards. 2000 AR226-1750 NEGzo7nd6ORZ14zrJJGbEVnmV 125
This document is a correspondence from DuPont Haskell Laboratory to the EPA, providing a summary of the U.S. uses of Ammonium Perfluorooctanoate (APFO), including its role as a fluoropolymer reaction aid, release data, industrial hygiene information, and employee blood data, while clarifying that DuPont does not manufacture APFO but purchases it from an external supplier 2000 AR226-1555 jg2934erwmLDBY5XED67KdJ0R 14
The document is an amended final report of a cell proliferation study conducted by 3M on N-Ethyl Perfluorooctanesulfonamido Ethanol (N-EtFOSE), Perfluorooctane Sulfonic Acid Potassium Salt (PFOS), and N-Ethyl Perfluorooctanesulfonamide (N-EtFOSA) in 2000 AR226-3630 yk76Vw09LDq03ez5rLymB3Jp2 74
The document is a final report from TherImmune Research Corporation detailing a cell proliferation study involving N-Ethyl Perfluorooctanesulfonamido Ethanol (N-EtFOSE), Perfluorooctane Sulfonic Acid Potassium Salt (PFOS), and N-Ethyl Perfluorooctanesulfonamide (PFOSA) in rats, sponsored 2000 AR226-3630 npGr6jRb7ORkQb2B6GawZOM32 62
The document contains attachments to a letter to C. Auer dated May 18, 2000, discussing studies and information related to perfluorooctane sulfonate (PFOS) and N-ethyl perfluorooctanesulfonamide (N-EtFOSA) that are believed to be in 3M's possession and relevant to the FIFRA docket. 2000 AR226-0377 ym4MxRmKJbGK9jE37GvarM6qX 2
3M submitted additional information to the EPA regarding perfluorooctane sulfonates and related compounds, including details on N-ethylperfluorooctane sulfonamidoethanol, N-methylperfluorooctanesulfonamidoethyl acrylate, and other perfluorinated compounds. 2000 AR226-0378 VJ0yvk4nDJ0gVj0LG84RwYjvo 8
The document contains attachments to a letter to C. Auer dated May 25, 2000, summarizing various acute toxicity studies on PFOA and its derivatives conducted by different laboratories, including inhalation and oral toxicity studies in rats and irritation studies in rabbits. 2000 AR226-0417 5bQBE8VYXGLr6RXOvmzB7BGRJ 7
3M is providing the EPA with supplemental information on perfluorooctanoic acid (PFOA) and perfluorooctane sulfonates (PFOS) related to environmental science and health effects, including studies on toxicity and environmental monitoring, as part of ongoing discussions about fluorochemistry. 2000 AR226-0416 238ZndX120xmEnm6Xv2ZOMbg 28
The document reports on a study conducted by Southern Research Institute to determine the percent protein binding of perfluorohexane sulfonate, perfluorooctane sulfonate, and perfluorooctanoate in human, rat, and monkey plasma, as well as various human-derived plasma protein fractions. 2000 AR226-1781 b5GdBBdrX7baRpmeapLREKOq6 47
The document contains a list of toxicology studies and mutagenicity tests conducted on perfluorooctanoic acid (PFOA) and its derivatives, primarily by 3M and various laboratories, detailing various assays and evaluations of their genotoxic effects. 2000 AR226-0428 4aE6RVzz2JY4VXN4DzpK6dLm1 19
This is a report amendment from Argus Research Laboratories regarding a fertility and developmental toxicity study of N-EtFOSE in rats, correcting Text Figure 1 without affecting the study results. 2000 AR226-1781 n95XOb34BvNnYN9qeLjao387m 2
The document details a laboratory-scale study on the thermal degradation of perfluorooctanesulfonate (PFOS) and related substances, specifically evaluating the potential environmental sources of PFOS from thermal degradation of fluorochemical compounds FC-807A and FC-1395. 2000 AR226-1781 xjdyaYoD74wm127qq5eyn0Gam 13
This final report details a flow-through bioconcentration test of Perfluorooctanesulfonate (PFOS) using bluegill fish (Lepomis macrochirus), conducted by Wildlife International, Ltd. for 3M Corporation, in compliance with EPA Good Laboratory Practice Standards. 2000 AR226-1781 dD2XL6bnZNnoL4KvXxmmX0Ko9 134
The document reports on the analysis of FC-143 content in serum and liver samples from a 90-day subacute toxicity study in rhesus monkeys, indicating adverse effects at higher dosage levels compared to a previous rat study, with both male and female monkeys accumulating FC-143 similarly. 2000 AR226-0448 6bzZaRxd843v8jLVKYN2OBgng 2
The document is an amended final report of a soil adsorption/desorption study of potassium perfluorooctanesulfonate (PFOS) conducted by 3M Environmental Laboratory, initiated on October 17, 2000, and compliant with TSCA Good Laboratory Practice standards. 2000 AR226-1781 zo5oJ8XMjBoqv1qrNqRy1Rxjm 24
The document discusses internal communications among DuPont employees regarding the preparation of a standby statement related to a 3M announcement on PFOS/PFOA, emphasizing the need for accuracy in media responses and clarifying the use of the statement. 2000 AR226-1666 9JbqY184n0Ep4vOEbn0r7gNy3 2
DuPont is seeking expert assistance to defend against a lawsuit from a farmer in West Virginia alleging health and environmental impacts related to PFOA from a non-hazardous landfill, despite their assessment indicating negligible risks to the farmer's cows. 2000 AR226-1676 BorzJ5xOer8Xa6XpLVDRezmm 1
This is a cover page from Pace Analytical Services, Inc. for the 3M Multi-city Food Study, prepared under contract with 3M, with project number 1039292. 2000 AR226-1781 LVKaRoGYEzvLEEZv08ygrm4q 1
The document is a correspondence from Wildlife International, Ltd. to 3M Corporation, providing addendums for studies on the solubility of PFOS in various mediums. 2000 AR226-1781 mqyQJxkXQpo3jGa2QELXnE1ZJ 1
The document is an addendum for a study on PFOS conducted by Wildlife International, Ltd., specifically detailing an Activated Sludge, Respiration Inhibition Test for 3M Corporation. 2000 AR226-1781 kZjQD5Yag9vekEzb8J5eNZ1O 1